A statement about prior postings and presentations: Posted at the European Society of Clinical Pharmacy's conference in Praha in October 2013 (link not available).
MAT-CAP: a novel medication assessment tool to explore adherence to clinical practice guidelines in community-acquired pneumonia†
Article first published online: 2 MAY 2014
Copyright © 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 23, Issue 9, pages 933–941, September 2014
How to Cite
2014), MAT-CAP: a novel medication assessment tool to explore adherence to clinical practice guidelines in community-acquired pneumonia, Pharmacoepidemiol Drug Saf, 23: 933–941. DOI: 10.1002/pds.3640, , and (
- Issue published online: 28 AUG 2014
- Article first published online: 2 MAY 2014
- Manuscript Accepted: 8 APR 2014
- Manuscript Revised: 4 APR 2014
- Manuscript Received: 11 DEC 2013
- clinical pharmacy;
- medication assessment tool;
- community-acquired pneumonia;
- clinical practice guidelines;
Community-acquired pneumonia (CAP) is a disease with high morbidity and mortality. Adherence to clinical practice guidelines (CPGs) in treatment of CAP is associated with favourable outcome. We aimed to develop and validate a medication assessment tool (MAT) to explore adherence to CPG recommendations in patients with CAP admitted to a Norwegian hospital. The tool is named MAT-CAP.
Sixteen quality indicators (QIs) based on local and international CPGs were developed. Content validity was explored in an expert panel using a two-round modified Delphi technique. QIs demonstrating content valdity were reformulated into review criteria forming the MAT-CAP. Feasibility and adherence to MAT-CAP were explored in a retrospective study using data from electronic patient records of CAP patients admitted to the University Hospital of North Norway Tromso during 2008. Reliability was explored using Cohen's kappa (ĸ) statistics for inter- and intra-observer agreements.
Content validity was demonstrated for 15 QIs covering areas as initial empirical treatment, microbiological diagnostics, pathogen specific treatment, dose adjustment according to renal function, switch from intravenous to oral treatment and treatment duration. Overall reliability was excellent with ĸ-values of 0.88 and 0.95 for inter-observer and intra-observer agreements, respectively. Overall applicability was 37.2%, and mean application times were 3.1 and 3.8 min for the two observers. Overall adherence to 812 criteria applied was 59% (range 0–100).
We have demonstrated content validity, feasibility and reliability of a 15-criterion MAT-CAP. Adherence results from applying MAT-CAP criteria pinpointed areas with good clinical performance and areas with improvement potentials. Copyright © 2014 John Wiley & Sons, Ltd.